NWBO: Once In A Decade Best Stock Investment -- Regulatory Approvals Coming! [Dec10, 2022 在第一页加了中文简述]

1686082325298.png
1686082353825.png
 
Volume is only about 1.88 millions today, decreased from the last two days. Yesterday about 15 min before market close, there was sudden surge of volume for about 1 million with share price being murdered from about 0.75 - 0.71.

But the reversed fortune continues, if only people know the reason of why, there should be more coming in the way of NWBO if institutions which are the losers of the sharp price drop of NVCR can find a way to invest in NWBO. A penny stock trading on OTC is a huge obstacle of course, but can money finds its way to nwbo just as water finds its way to the ocean?

1686254999824.png
1686254978263.png
 
最后编辑:
The above review article does what a review article should do: poking and criticizing everything so far has been done. The authors wrote the article as if they are talking something (JAMAOncology paper by Liau et al) they cannot achieve. Anyhow, nothing new there and it is easy saying than done.

We are heading to approvals anyhow by all RAs involved. And the uptrend trajectory in recent days still intact and should intensify.
 
最后编辑:

FDA approvals may move UCLA brain cancer and Alzheimer’s treatments from bench to bedside​


Glioblastoma and Alzheimer’s disease treatments advance through clinical trials.

www.uclahealth.org

FDA approvals may move UCLA brain cancer and Alzheimer’s treatments from bench to bedside

“An institution like UCLA offers patients with progressive and ultimately life-ending diseases the opportunity to participate in trials that may benefit them, but the primary goal of any clinical trial is to provide benefit to others.”
www.uclahealth.org www.uclahealth.org
 
NBC nightly news ran a story on Survax M vaccine for GBM.

Any opinion on Survax M?

How come we don’t see NBC reporting on DCVax for GBM?
 
Yes saw (read) that coverage by NBC. Survax's p2 trial is still recruiting as of today and after that there will be three years for data collection for the primary endpoint of overall survival. And if successful, the company will run a P3 trial which will take several more years to recruit and complete. So at this point it is not a peer competitor.

In addition, Survax targets only one or two antigen (I don't remember exactly) while DCVax-L targets the whole set of antigens of the GBM tumors. So theoretically and also from what Linda Liau has done in UCLA, Survax should not work as good as DCVax-L.

As for why we have not seen any coverage on NBC yet, this is a mystery. They could be a lot of different explanations: it could be the US biotech mafia as someone has called them who hasn't reported our story as DCVax is a threat to what they have represented, ie, big pharms, or it may be DCVax story is not new. When DCVax-L in P1/2 trial and in early P3 trial, major US media did report in print and also in TVs.

But I read some tweets this morning, some GBM patient and investors have contacted the NBC lady who wrote the recent Survax story, asking her to get into DCVax-L story, particularly after P3 results have been published in JAMA Oncology. She seems to say she will follow.

Nothing we can do really. I am just patiently waiting the inevitable news. In the meanwhile, accumulate more shares as I have unwavering belief DCVax-L will be approved for GBM, followed by other solid cancers.

Best.
 
您必须登录或注册才可回复。
后退
顶部